Zacks Investment Research on MSN

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck MRK is a prominent pharmaceutical company with a strong position in oncology. Its blockbuster drug, Keytruda, and new ...
Hosted on MSN

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of $2.13 per ...